FFAR4 and osteoporosis: Overall, the DHA-FFAR4 axis may provide a potential therapeutic target for osteoporosis, rheumatoid/osteoarthritis, and OTM-associated bone loss and should be followed up with further clinical experiments and the development of highly selective FFAR4 agonists to achieve precise therapeutic effects.